2026-06-08T07:26:35Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1240782025-09-18T00:03:21Zcom_20.500.14352_14col_20.500.14352_15

Hydrocortisone Aceponate for Chronic Otitis: Long‐Term Efficacy Lorente Méndez, María del Carmen Alonso Miguel, Daniel 636.09:616 Canine Chronic otitis externa Hydrocortisone aceponate Proactive treatment Reactive treatment Recurrent otitis externa. Patología veterinaria 3109.07 Patología Author Contributions: C. Lorente-Méndez: conceptualisation, methodology, acquisition andinterpretation of data and writing. D. Alonso-Miguel: acquisition,analysis and interpretation of data and writing. Background: Effective management of otitis externa (OE) requires addressing all contributing factors to prevent chronicityand recurrence. Evidence on the long-term efficacy of topical corticosteroids in preventing recurrence and secondary infectionsremains limited.Objectives: This retrospective noncontrolled study evaluated the efficacy of hydrocortisone aceponate (HCA) in resolving non-infectious chronic or recurrent (CR)- OE with or without proliferative changes, and preventing recurrence of acute episodes andsecondary infections.Animals: A total of 63 owned dogs (115 ears) with unilateral or bilateral non-infectious CR- OE were included. Most ears wereenrolled after resolving infectious otitis, as persistent inflammation or recurrence required further management.Materials and Methods: Clinical records from two dermatology referral centres (February 2022–July 2023) were reviewed.Dogs were included if they had recurrent otitis for over a year (≥ 1 year) or chronic otitis (≥ 1 month). Otitis severity was assessedusing the Otitis Index Score (OTIS3) scale, and by grading stenosis and hyperplasia severity. Enrolled patients received HCA0.584 mg/mL at weight-adjusted doses. A reactive phase continued until OTIS3 < 2, followed by a proactive phase with regimensadapted to otitis severity. Concurrent treatments were recorded.Results: Recurrence was not observed in 79.1% of ears (mean follow-up 202.6 days). Among 24 relapsed ears, 29.17% recurredafter treatment discontinuation. Higher recurrence was associated with stopping therapy (p < 0.001) and recent bacterial otitis(p = 0.015). No adverse effects were noted.Conclusions and Clinical Relevance: The use of HCA appears to be an effective and safe option for reactive and proactivemanagement of non-infectious CRC- OE, reducing recurrences and improving patient and owner quality-of-life Background: Effective management of otitis externa (OE) requires addressing all contributing factors to prevent chronicityand recurrence. Evidence on the long-term efficacy of topical corticosteroids in preventing recurrence and secondary infectionsremains limited. Objectives: This retrospective noncontrolled study evaluated the efficacy of hydrocortisone aceponate (HCA) in resolving non-infectious chronic or recurrent (CR)- OE with or without proliferative changes, and preventing recurrence of acute episodes andsecondary infections. Animals: A total of 63 owned dogs (115 ears) with unilateral or bilateral non-infectious CR- OE were included. Most ears wereenrolled after resolving infectious otitis, as persistent inflammation or recurrence required further management. Materials and Methods: Clinical records from two dermatology referral centres (February 2022–July 2023) were reviewed.Dogs were included if they had recurrent otitis for over a year (≥ 1 year) or chronic otitis (≥ 1 month). Otitis severity was assessedusing the Otitis Index Score (OTIS3) scale, and by grading stenosis and hyperplasia severity. Enrolled patients received HCA0.584 mg/mL at weight-adjusted doses. A reactive phase continued until OTIS3 < 2, followed by a proactive phase with regimensadapted to otitis severity. Concurrent treatments were recorded. Results: Recurrence was not observed in 79.1% of ears (mean follow-up 202.6 days). Among 24 relapsed ears, 29.17% recurredafter treatment discontinuation. Higher recurrence was associated with stopping therapy (p < 0.001) and recent bacterial otitis(p = 0.015). No adverse effects were noted. Conclusions and Clinical Relevance: The use of HCA appears to be an effective and safe option for reactive and proactivemanagement of non-infectious CRC- OE, reducing recurrences and improving patient and owner quality-of-life Depto. de Medicina y Cirugía Animal Fac. de Veterinaria TRUE pub 2025-09-17T15:04:46Z 2025-09-17T15:04:46Z 2025 journal article VoR https://hdl.handle.net/20.500.14352/124078 0959-4493 10.1111/vde.70008 1365-3164 eng Lorente-Méndez, C., & Alonso-Miguel, D. (2025). Hydrocortisone Aceponate for Chronic Otitis: Long-Term Efficacy. Veterinary dermatology, 10.1111/vde.70008. Advance online publication. https://doi.org/10.1111/vde.70008 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ open access application/pdf Wiley